MARKER THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.05 USD | -1.58% |
|
-8.47% | -26.36% |
| Apr. 30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
| Mar. 27 | North American Morning Briefing : Stocks Edge -2- | DJ |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 251.8 | 131.7 | 69.64 | 78.94 | 22.71 | 48.89 |
| Enterprise Value (EV) 1 | 190.1 | 88.26 | 60.54 | 48.46 | 18.54 | 33.78 |
| P/E ratio | -0.72 x | -6.13 x | -2.38 x | -1.73 x | -0.74 x | -5.88 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1,222 x | 618 x | 149 x | 63.6 x | 2.52 x | 14.8 x |
| EV / Revenue | 923 x | 414 x | 130 x | 39 x | 2.06 x | 10.2 x |
| EV / EBITDA | - | -3,936,189 x | -2,131,721 x | -1,298,150 x | -682,816 x | -2,864,432 x |
| EV / FCF | -2.61 x | -7.91 x | -3.12 x | -3.73 x | -0.89 x | -3.33 x |
| FCF Yield | -38.3% | -12.6% | -32.1% | -26.8% | -113% | -30% |
| Price to Book | 4.25 x | 2.99 x | 2.69 x | 1.79 x | 1.14 x | 3.48 x |
| Nbr of stocks (in thousands) | 4,537 | 4,572 | 4,803 | 8,308 | 8,540 | 8,889 |
| Reference price 2 | 55.50 | 28.80 | 14.50 | 9.502 | 2.659 | 5.500 |
| Announcement Date | 3/15/19 | 3/12/20 | 3/9/21 | 3/17/22 | 3/22/23 | 3/26/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.206 | 0.2132 | 0.4668 | 1.242 | 9.014 | 3.311 |
| EBITDA | - | -22.42 | -28.4 | -37.33 | -27.16 | -11.79 |
| EBIT 1 | -144.2 | -22.53 | -28.89 | -39.48 | -29.95 | -14.58 |
| Operating Margin | -69,988.27% | -10,567.28% | -6,188.25% | -3,179.32% | -332.23% | -440.37% |
| Earnings before Tax (EBT) 1 | -148 | -21.43 | -28.71 | -41.88 | -29.93 | -14.04 |
| Net income 1 | -148 | -21.43 | -28.71 | -41.88 | -29.93 | -8.237 |
| Net margin | -71,826.32% | -10,050.92% | -6,149.74% | -3,372.68% | -332.06% | -248.76% |
| EPS 2 | -77.50 | -4.700 | -6.102 | -5.500 | -3.584 | -0.9350 |
| Free Cash Flow 1 | -72.82 | -11.16 | -19.43 | -12.98 | -20.92 | -10.14 |
| FCF margin | -35,351.23% | -5,234.45% | -4,162.3% | -1,045.55% | -232.09% | -306.27% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/15/19 | 3/12/20 | 3/9/21 | 3/17/22 | 3/22/23 | 3/26/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.242 | 0.9643 | 0.7905 | 3.95 | 3.309 |
| EBITDA | - | - | - | - | - | - |
| EBIT | -10.02 | -9.764 | -9.795 | -9.28 | -7.019 | - |
| Operating Margin | - | -786.36% | -1,015.72% | -1,173.92% | -177.72% | - |
| Earnings before Tax (EBT) | -12.43 | -9.763 | -9.911 | -9.244 | -6.92 | - |
| Net income | -12.43 | -9.763 | -9.911 | -9.244 | -6.92 | - |
| Net margin | - | -786.28% | -1,027.72% | -1,169.4% | -175.2% | - |
| EPS 2 | -1.500 | -1.100 | -1.200 | -1.100 | -0.8000 | -3.270 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/17/22 | 5/13/22 | 8/11/22 | 11/10/22 | 3/22/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 61.7 | 43.4 | 9.1 | 30.5 | 4.17 | 15.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -72.8 | -11.2 | -19.4 | -13 | -20.9 | -10.1 |
| ROE (net income / shareholders' equity) | -470% | -41.4% | -80.4% | -117% | -94.1% | -83.5% |
| ROA (Net income/ Total Assets) | -268% | -26% | -39.3% | -43.4% | -36.5% | -35.4% |
| Assets 1 | 55.27 | 82.56 | 73.12 | 96.53 | 82 | 23.3 |
| Book Value Per Share 2 | 13.10 | 9.640 | 5.390 | 5.290 | 2.330 | 1.580 |
| Cash Flow per Share 2 | 13.60 | 9.600 | 4.210 | 5.100 | 1.400 | 1.700 |
| Capex 1 | 0.15 | 0.37 | 10.4 | 3.13 | 4.95 | - |
| Capex / Sales | 71.69% | 175.89% | 2,233.99% | 252.16% | 54.86% | - |
| Announcement Date | 3/15/19 | 3/12/20 | 3/9/21 | 3/17/22 | 3/22/23 | 3/26/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -26.36% | 36.1M | |
| +0.17% | 42.19B | |
| +10.92% | 42.24B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +5.23% | 24.63B | |
| -24.79% | 18.2B | |
| +26.69% | 12.01B | |
| -3.13% | 11.76B | |
| +6.57% | 10.4B |
- Stock Market
- Equities
- MRKR Stock
- Financials Marker Therapeutics, Inc.
